 CAMBRIDGE, Mass., Sept. 20, 2021 GLOBE NEWSWIRE -- Immuneering Corporation Nasdaq: IMRX, a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that Immuneering Corporation has been selected to be added to the Russell 2000 Index effective September 20, 2021, after the close of the U.S. equity markets. 